DDInter649 DDInter1016
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile,
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP3A4
Enzalutamide {u} (Compound) upregulates {v} (Gene) RPL39L
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Enzalutamide {u} (Compound) causes {v} (Side Effect) Musculoskeletal pain
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Enzalutamide (Compound) resembles Nilutamide (Compound)
Enzalutamide (Compound) resembles Bicalutamide (Compound)
Enzalutamide (Compound) binds CYP3A4 (Gene)
Enzalutamide (Compound) upregulates RPL39L (Gene)
Enzalutamide (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Enzalutamide (Compound) causes Musculoskeletal pain (Side Effect)
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir